Cascade Pharmaceuticals, Inc
Clinical trials sponsored by Cascade Pharmaceuticals, Inc, explained in plain language.
-
New drug trial targets rare liver disease
Disease control OngoingThis study is testing an investigational drug called CS0159 for people with Primary Sclerosing Cholangitis (PSC), a rare disease that scars the bile ducts in the liver. About 50 participants will be randomly assigned to receive either the drug or a placebo for 12 weeks, followed …
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for liver disease patients in clinical trial
Disease control OngoingThis study is testing an experimental drug called CS0159 for people with Primary Biliary Cholangitis (PBC), a chronic liver disease. It will involve 75 participants and last about one year, with the first 12 weeks comparing the drug to a placebo. The main goals are to see if CS01…
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC